Archive | Biopharmaceuticals

Rayno Biopharmaceuticals Portfolio Winners July ’12 YTD: ALXN,IMGN,PCYC,REGN,SGEN Etc.

http://goldenbeeltd.com/?page_id=3108 Biotechnology Sector Remains Strong Despite High Valuations The Rayno Biopharmaceuticals Portfolio is outperforming most of the biotech indices and ETF’s with many winners over 50% YTD. The best trade for June was long Pharmacyclics (PCYC) and  short Medivation(MDVN) for a net profit of 51%. In one of the best years since 1999 for the biotechnology sector our core […]

Continue Reading 0

Supreme Court Obamacare Ruling: Mixed Reaction For Healthcare Stocks- Update 1 Market Soars

can you order Gabapentin online Update 1   Mid-day Trading -June 29 Bulls Back in Charge on EU Bank Bailout The market has forgotten about Obamacare and reverted to the number one market issue-Euro debt resolution. Here is a healthcare sector update from today’s trading and our take: Biotechnology: Stocks have resumed their run to all time highs and even mid-caps […]

Continue Reading 0

Biotechnology Stocks Continue To Rally After BIO Meeting in Boston

п»ї100mg neurontin BioBuzz Rolls On After a bad day on NASDAQ yesterday with some profit taking in biotech there is a lot of green screen today. The sector is up 1% today and we are near all time highs like the XBI ($86.92). But to many investors, biotechnology is relatively unknown or still perceived as a speculative […]

Continue Reading 0

Rayno Life Science Market Update: CELG, ONXX, XBI Update 1

Sell-off gets worse with S&P down 2%. Moody’s downgrade of banks expected by end of day. Bear market for commodities? ———– We have been at BIO 2012 in Boston over the past week and will provide interesting trends and data from the Meeting by Monday. Global Slowdown Fears: Market off 1.5% at mid-day with the […]

Continue Reading 0

Very Limited ASCO Boost For Biotechnology Stocks – Update 1 PCYC

A Biopharma Stock We Missed-Pharmacyclics (PCYC $38.21) up 9.89% today It is unbelievable that we missed the huge move in PCYC up 157% YTD with a one year range of 7.63 to 38.56. The market cap is $2.63B. The Company has a robust pipeline of products led by Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor […]

Continue Reading 0

Rayno Life Science Portfolio Gets ASCO Boost With Antibody Drug Conjugates

Antibody Drug Conjugates Make Progress for Cancer Therapy- Immunogen and Seattle Genetics Many of our focus stocks were up today helped by a late day rally that brought the NASDAQ up 0.46% at the close. Major biotechnology ETF’s (IBB,XBI) also recovered with some green by the end of the day.The Rayno Life Science Portfolio was […]

Continue Reading 0

Todays’ Sell-Off Finally Hits Resilient Biotech Stocks

Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850,  we see a lot of countertrends like gold up $39.70 off recent lows to $1576 accompanied by a big rally in silver and other metal stocks […]

Continue Reading 0

Biotech Sector Avoids Nasty Correction and Hits New Highs

Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P […]

Continue Reading 0

Rayno Life Science Update-Macro Rules, Risk Off

Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off  down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only 1.92% over five days and still up 18% YTD […]

Continue Reading 0

Market Sell-Off Continues: Biotechs Follow NASDAQ Down 1.56%

The NASDAQ Biotechnology Index IBB ($122.30)  is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this week we urged investors […]

Continue Reading 0